Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 11,355

Document Document Title
WO/2010/037224A1
Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention ...  
WO/2010/039048A1
The present invention relates to an immunostimulant and to the use of an immunostimulant in the form of a cross-linked muramyl dipeptide microparticle in the treatment of radiation exposure, radiation poisoning, and mitigating the toxic ...  
WO/2010/034118A1
There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid deri...  
WO/2010/035076A1
The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5 -FU dose administered by continuous infusion in patients treated b...  
WO/2010/035806A1
A solid preparation which contains a compound (I) or a salt thereof, a pH adjuster and a calcium antagonist, while having excellent dissolvability and stability.  
WO/2010/032489A1
An iron chelating agent which can selectively chelate iron ions. The iron chelating agent is characterized by being composed of a compound represented by formula (1) or a salt thereof. (In formula (1), ring Z represents an aromatic hyd...  
WO/2010/028503A1
A cysteine-rich undenatured whey-derived protein formulation did not interfere with the tumor-cytotoxic effects of chemotherapy and radiation therapy and did not have a negative effect on the clinical outcome, that is, negatively affect ...  
WO/2010/028596A1
The composition containing ferulic acid and matrine compounds, the use and the preparation thereof. The composition containing ferulic acid and matrine compounds can enhance pharmaceutical effects of both ferulic acid and matrine compoun...  
WO/2010/027488A3
The invention provides heterochimeric antibodies and/or fragments thereof comprising: (i) hypervariable region sequences wholly or substantially corresponding to sequences found in antibodies from a donor species; (ii) constant region se...  
WO/2010/017332A3
Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, pept...  
WO/2010/015827A2
Phosphate binding materials and compositions comprising them which are solid ligand-modif ied poly oxo-hydroxy metal ion materials are disclosed that are based on ferric iron oxo- hydroxides modified with carboxylic acid ligands, or ioni...  
WO/2010/017332A2
Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, pept...  
WO/2010/015827A3
Phosphate binding materials and compositions comprising them which are solid ligand-modif ied poly oxo-hydroxy metal ion materials are disclosed that are based on ferric iron oxo- hydroxides modified with carboxylic acid ligands, or ioni...  
WO/2010/014870A2
Disclosed is a composition for use as an antioxidant, such as for use as an anti-aging supplement. The composition can include a muscadine (Vitis rotundifolid) pomace extract having a polyphenol content of at least 2% and trans- resverat...  
WO/2010/014873A3
Disclosed herein is a method of producing a muscadine pomace extract. The method can include combining a bronze muscadine pomace extract with a purple muscadine pomace extract to produce a muscadine pomace extract, wherein the ratio of b...  
WO/2010/013987A2
Disclosed herein is an extraction method for increasing liquiritigenin content in Glycyrrhizae Radix et Rhizoma or Glycyrrhizae radix extract, the method comprising: using water, an organic solvent, or a mixed solvent of water and the or...  
WO/2010/014873A2
Disclosed herein is a method of producing a muscadine pomace extract. The method can include combining a bronze muscadine pomace extract with a purple muscadine pomace extract to produce a muscadine pomace extract, wherein the ratio of b...  
WO/2010/013987A3
Disclosed herein is an extraction method for increasing liquiritigenin content in Glycyrrhizae Radix et Rhizoma or Glycyrrhizae radix extract, the method comprising: using water, an organic solvent, or a mixed solvent of water and the or...  
WO/2010/013987A4
Disclosed herein is an extraction method for increasing liquiritigenin content in Glycyrrhizae Radix et Rhizoma or Glycyrrhizae radix extract, the method comprising: using water, an organic solvent, or a mixed solvent of water and the or...  
WO/2010/013551A1
Disclosed is a preparation for oral administration, which is improved in the bitter taste attributed to quercetin glycoside. Water-extracted chondroitin sulfate is added to a preparation for oral administration comprising quercetin glyco...  
WO/2010/014870A3
Disclosed is a composition for use as an antioxidant, such as for use as an anti-aging supplement. The composition can include a muscadine (Vitis rotundifolid) pomace extract having a polyphenol content of at least 2% and trans- resverat...  
WO/2010/011533A3
Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrel...  
WO/2010/011533A2
Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrel...  
WO/2010/006809A2
Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1 ...  
WO/2010/006634A1
The invention relates to the field of radiation injury. More particularly, this invention relates to the protection against/prevention of and treatment of diseases caused by ionizing radiation by the use of thrombomodulin.  
WO/2010/006809A3
Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1 ...  
WO/2010/003178A1
The present invention relates generally to the field of synthetic vaccines, components thereof and methods for producing same. More particularly, the present invention provides a component of synthetic vaccines and its use in a modular a...  
WO/2010/005012A1
Provided is a composition which comprises apolactoferrin together with at least one member selected from the group consisting of an advanced glycation end product-binding agent, an antioxidant and an antibacterial substance. The advance...  
WO/2010/003092A1
Methods of treating an inflammatory disorder and inhibiting inflammation by administering an inhibitor of a pH-activated protease are provided.  
WO/2010/000013A1
The present invention relates to a sulfated polysaccharide compound and the preparation and use thereof, and in particular to a narrow distribution low molecular weight, highly sulfated pentosan (in this instance a xylan) referred to as ...  
WO/2010/000964A1
Method for the microbiological production of cinnamoyl amide derivatives of amino acids, certain products that result therefrom and uses thereof, especially as antioxidants.  
WO/2009/157886A1
The invention relates to pharmacology and medicine and can be used in developing agents for treating immune and oncological diseases, in particular skin neoplasms in the form of melanomas. The inventive composite agent Samirin comprises ...  
WO/2009/157575A1
Disclosed are a skin preparation for external use, a whitening agent, an anti-aging agent, and an antioxidant, which are highly safe and excellent in melanin generation control effects, anti-aging effects, or antioxidation effects. One o...  
WO/2009/153665A2
The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.  
WO/2009/153457A3
The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effect...  
WO/2009/153665A3
The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.  
WO/2009/144253A1
Compounds comprising a 3-pyridinol or 5-pyrimidinol ring carrying an organoseleno- or organotelluro- substituent on the pyridine or pyrimidine ring, exhibit useful antioxidant properties. The compounds may for example be in accordance wi...  
WO/2009/141543A1
The invention relates to the cosmetic use of an effective quantity of a berry extract, the berry being selected from wolfberries, blueberries, cranberries, blackberries, gooseberries, white currants, the raspberries, sea buckthorns, stra...  
WO/2009/139361A1
Disclosed is a glucocorticoid receptor agonist composed of a compound represented by formula (1) or a salt thereof, which is a 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative having a substituted oxy group. A novel pharmacologi...  
WO/2009/135352A1
A plum tree extract comprises 0.5-50 wt% squalene The plum tree extract mainly comes from fat-soluble portion and/or water-soluble portion of non-fruit part of plum tree A method for preparing the plum tree extract, comprises using super...  
WO/2009/135918A1
The present invention provides a topical or therapeutic composition comprising a flavan-3-ol compound or a non-naturally occurring derivative thereof. The composition may for example be an anti-ageing composition or a composition for the...  
WO/2009/135311A1
An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well as an extract obtained by this process. Compositions comprising s...  
WO/2009/135311A8
An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well as an extract obtained by this process. Compositions comprising s...  
WO/2009/133647A1
Disclosed are: a method for covalently binding a cyclic nitroxide radical compound to a hydrophobic block in a specific hydrophilic-hydrophobic block copolymer; a polymerized cyclic nitroxide radical compound which is produced through th...  
WO/2009/133964A1
Disclosed is a novel agent for preventing oxidative stress. The agent for preventing oxidative stress comprises 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2- ylthio)butanoic acid, 4-(1-((naphthalen-1- yl)methyl)benzimidazol-2...  
WO/2009/129592A1
An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per litre of liquid composition, an effect...  
WO/2009/129616A1
The invention provides methods of preventing or treating diseases or disorders caused by biological agents or chemical agents in a subject (e.g., a mammal, such as a human) by administering genetically modified human umbilical cord periv...  
WO/2009/130604A3
Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (...  
WO/2009/130604A2
Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (...  
WO/2009/127982A2
A method of synthesizing carboxylated amines is disclosed. The method comprises reacting a mixture of a potassium salt of either a primary or secondary amine with a potassium salt of a halogenated carboxylic acid wherein the halogenated ...  

Matches 601 - 650 out of 11,355